Membership

Our membership has grown significantly since our organisation was founded in 2000, doubling in the last seven years to over 1,000. ANZGOG's members in every Australian state and New Zealand and are dedicated to growing the research portfolio in both treatment, surgery, radiation oncology, quality of life and survivorship. Together with our staff, donors and partners, our members work to improve life for women through cancer research.

As at 30th June 2020:

Membership Growth 2010-2020:

Grouped by professional field

Membership group pie chart

PERFORMANCE MEASURES

ANZGOG regularly reviews its performance against the five strategic goals, in the areas of:

  1. Innovative & equitable clinical trials in gynaecological cancers.
  2. World-class translational research in gynaecological cancers.
  3. Capacity building for gynaecological cancer research in Australia and New Zealand.
  4. Strategic partnerships, collaboration & engagement.
  5. Organisational capacity aligned with our research agenda.

Financial Summaries

STATEMENT OF FINANCIAL POSITION
Year ending 30 June 2020
Assets
2020
2019
Total current assets
$2,052,671
$2,575,374
Total non-current assets
$4,503,615
$4,644,330
Total assets
$6,556,286
$7,219,704
LIABILITIES
Total current liabilities
$2,185,428
$2,148,884
Total non-current liabilities
$17,760
Total liabilities
$2,203,188
$2,148,884
Net Assets
$4,353,098
$5,070,820
Equity
New Research Fund Reserve
$259,041
$397,150
Beneficiary Fund Reserve
$339,717
$209,267
OASIS Initiative Reserve
$2,009,116
$1,864,407
Retained Surplus
$1,745,224
$2,599,996
Total Equity
$4,353,098
$5,070,820
STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME
Year ending 30 June 2020
REVENUE
2020
2019
Grants - Gov, Philanthropy, Other
$1,892,682
$1,687,323
Fundraising
$575,431
$590,427
ASM Conference
$3,374
$301,989
Interest and other Income
$301,420
$179,935
Jobkeeper Support
$119,571
$0
Total Revenue
$2,892,478
$2,759,674
Expenses
2020
2019
Trial Expenses
($956,879)
($536,319)
Finance and Operations Expenses
($312,674)
($331,485)
Employee Benefit Expenses
($1,424,010)
($1,198,183)
Fundraising Expenses
($160,865)
($247,762)
Communications, ASM, Education
($176,990)
($324,942)
TOTAL OPERATING EXPENSES
($3,031,418)
($2,638,691)
Surplus (deficit) from Operations
($138,940)
$120,983
Project and Grant expenses utilitising ANZGOG reserves
($235,231)
($389,109)
Net change in fair value of other financial assets
($343,551)
$109,271
Total Comprehensive Income for the year
($717,722)
($158,855)
In 2020, ANZGOG applied $235,231 of its reserves to Research Projects. It also accounted for a net change in fair value of its investments of $343,551 due to COVID-19 impacts.
Download the full Annual Financial Report for the year ending 30 June 2020, audited by BDO East Coast Partnership:
Download

FUNDING

Research

ANZGOG has a collaborative agreement with the University of Sydney which supports the operation of a number of ANZGOG trials by the NHMRC Clinical Trials Centre (CTC). The University of Sydney is sponsor of these trials (ANZGOG also a trial sponsors in its own right).

GOVERNMENT GRANT SUPPORT

Government grant funding for the benefit of ANZGOG clinical trials projects is administered by the University of Sydney and is received annually to support these research activities. In 2020, $4,158,510 in government grants and other funding was received by the University of Sydney for ANZGOG’s research projects, bringing the total since 2002 to $23,500,425. These funds are not reported in the ANZGOG Annual Financial Statements but are received for ANZGOG projects by the University of Sydney as a result of our collaboration.

RESEARCH PROJECT FUNDING

Significant trial funds received and administered by the University of Sydney in 2020 were:
SOLACE2
$462,621
STATEC
$258,545
ADELE
$1,121,925
PARAGON-II
$1,497,941

SUPPORT FOR CLINICAL TRIALS

The Cancer Australia Support for Cancer Clinical Trials Program, which is shared 50:50 with the University of Sydney, NHMRC Clinical Trials Centre, provides $500,000 annually and 50% this figure is included in income statements.